196 related articles for article (PubMed ID: 2440124)
21. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
22. The contribution of activated factor XIII to fibrinolytic resistance in experimental pulmonary embolism.
Reed GL; Houng AK
Circulation; 1999 Jan; 99(2):299-304. PubMed ID: 9892598
[TBL] [Abstract][Full Text] [Related]
23. Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII.
Rijken DC; Abdul S; Malfliet JJ; Leebeek FW; Uitte de Willige S
J Thromb Haemost; 2016 Jul; 14(7):1453-61. PubMed ID: 27148673
[TBL] [Abstract][Full Text] [Related]
24. Determinants of substrate specificity for factor XIII.
McDonagh J; Fukue H
Semin Thromb Hemost; 1996; 22(5):369-76. PubMed ID: 8989819
[TBL] [Abstract][Full Text] [Related]
25. Carbon monoxide-releasing molecule-2 decreases fibrinolysis in human plasma.
Nielsen VG; Kirklin JK; George JF
Blood Coagul Fibrinolysis; 2009 Sep; 20(6):448-55. PubMed ID: 19581800
[TBL] [Abstract][Full Text] [Related]
26. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
[TBL] [Abstract][Full Text] [Related]
27. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
Sabovic M; Lijnen HR; Keber D; Collen D
Thromb Haemost; 1989 Dec; 62(4):1083-7. PubMed ID: 2515603
[TBL] [Abstract][Full Text] [Related]
28. Inherited fibrinolytic disorder due to an enhanced plasminogen activator level.
Aznar J; Estellés A; Vila V; Regañón E; España F; Villa P
Thromb Haemost; 1984 Oct; 52(2):196-200. PubMed ID: 6543037
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
30. Activated protein C increases fibrin clot lysis by neutralization of plasminogen activator inhibitor--no evidence for a cofactor role of protein S.
de Fouw NJ; de Jong YF; Haverkate F; Bertina RM
Thromb Haemost; 1988 Oct; 60(2):328-33. PubMed ID: 2975409
[TBL] [Abstract][Full Text] [Related]
31. Hydroxyethyl starch enhances fibrinolysis in human plasma by diminishing alpha2-antiplasmin-plasmin interactions.
Nielsen VG
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):647-56. PubMed ID: 17890952
[TBL] [Abstract][Full Text] [Related]
32. Effects of ethanol on human blood fibrinolysis and coagulation.
Olsen H; Osterud B
Alcohol Alcohol Suppl; 1987; 1():591-4. PubMed ID: 3426737
[TBL] [Abstract][Full Text] [Related]
33. The in vivo effect of fibrinogen and factor XIII on clot formation and fibrinolysis in Glanzmann's thrombasthenia.
Shenkman B; Livnat T; Misgav M; Budnik I; Einav Y; Martinowitz U
Platelets; 2012; 23(8):604-10. PubMed ID: 22273510
[TBL] [Abstract][Full Text] [Related]
34. alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder.
Kluft C; Nieuwenhuis HK; Rijken DC; Groeneveld E; Wijngaards G; van Berkel W; Dooijewaard G; Sixma JJ
J Clin Invest; 1987 Nov; 80(5):1391-400. PubMed ID: 2445779
[TBL] [Abstract][Full Text] [Related]
35. Fibrinogen depletion after plasma-dilution: impairment of proteolytic resistance and reversal via clotting factor concentrates.
He S; Johnsson H; Zabczyk M; Hultenby K; Wallén H; Blombäck M
Thromb Haemost; 2014 Mar; 111(3):417-28. PubMed ID: 24196490
[TBL] [Abstract][Full Text] [Related]
36. Release of alpha 2-plasmin inhibitor from plasma fibrin clots by activated coagulation factor XIII. Its effect on fibrinolysis.
Mimuro J; Kimura S; Aoki N
J Clin Invest; 1986 Mar; 77(3):1006-13. PubMed ID: 2419360
[TBL] [Abstract][Full Text] [Related]
37. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
Watahiki Y; Scully MF; Ellis V; Kakkar VV
Thromb Haemost; 1989 Jun; 61(3):502-6. PubMed ID: 2508259
[TBL] [Abstract][Full Text] [Related]
38. Effect of a selective thrombin inhibitor MCI-9038 on fibrinolysis in vitro and in vivo.
Tamao Y; Yamamoto T; Kikumoto R; Hara H; Itoh J; Hirata T; Mineo K; Okamoto S
Thromb Haemost; 1986 Aug; 56(1):28-34. PubMed ID: 2877508
[TBL] [Abstract][Full Text] [Related]
39. Investigation of a link between raised levels of pepsinogen in blood as a mediator of in-vitro clot lysis in acid and a cause of abnormal factor XIII screening tests.
Duncan EM; Dale BJ; Lloyd JV
Blood Coagul Fibrinolysis; 2014 Jun; 25(4):340-8. PubMed ID: 24440916
[TBL] [Abstract][Full Text] [Related]
40. Clot structure modification by fondaparinux and consequence on fibrinolysis: a new mechanism of antithrombotic activity.
Varin R; Mirshahi S; Mirshahi P; Kierzek G; Sebaoun D; Mishal Z; Vannier JP; Yvonne Borg J; Simoneau G; Soria C; Soria J
Thromb Haemost; 2007 Jan; 97(1):27-31. PubMed ID: 17200767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
